Physician profile
Anuj Goyal
NPI 1144214818
$27,653.52
in general payments reported to CMS, 2019-2025
37 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $2,035 · 2021: $6,160 · 2022: $8,118 · 2023: $2,382 · 2024: $5,272 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,458 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,350 · Education: $217 · Travel and Lodging: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,458.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,350.00 |
| Education | $217.32 |
| Travel and Lodging | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,137.63 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $2,448.70 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,081.85 | 2019-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,037.53 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $981.41 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $815.07 | 2020-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $762.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $400.56 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Amgen INC. | $375.29 | 2021-2025 | Tezspire |
| Axsome Therapeutics, INC. | $324.95 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $271.39 | 2021-2024 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $219.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.57 | 2020-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $197.44 | 2019-2025 | |
| Inspire Medical Systems, INC. | $194.79 | 2023 | Inspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $183.74 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $136.15 | 2020-2024 | Yupelri |
| Pulmonx Corporation | $102.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Lilly USA, LLC | $89.98 | 2025 | Zepbound |
| Baxter Healthcare | $83.30 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $83.06 | 2021-2022 | |
| Shionogi INC | $74.66 | 2022-2023 | Fetroja |
| Philips North America LLC | $65.41 | 2020-2024 | (Ak6) Vest Therapy |
| Viatris Specialty LLC | $53.18 | 2025 | Yupelri |
| Gilead Sciences, INC. | $35.47 | 2021 | |
| Paratek Pharmaceuticals, INC. | $32.72 | 2022 | |
| Astellas Pharma US INC | $23.22 | 2022 | |
| Nabriva Therapeutics, Plc | $20.48 | 2021 | |
| Shire North American Group INC | $20.08 | 2019 | |
| Advanced Respiratory, INC | $18.86 | 2021 | |
| Verona Pharma, INC. | $17.80 | 2025 | Ohtuvayre |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Kaleo, INC. | $14.75 | 2022 | |
| Resmed Corp | $14.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $7.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.